It is the established policy of the Drug, Chemical & Associated Technologies Association and all of its operating committees to conduct their operations in strict compliance with the antitrust laws of the United States of America. The DCAT antitrust policy prohibits any discussions which constitute or imply any agreement or understanding concerning:
Meetings of the DCAT Executive Committee, Board of Directors and all standing committees shall be conducted pursuant to agendas distributed to attendees and minutes of these meetings shall be distributed to attendees promptly. Actions taken at these meetings will be reported to the membership on a regular basis.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.